301 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Internal Medicine Audio PeerVoice

    • Science
    • 4.5 • 2 Ratings

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Managing Generalised Myasthenia Gravis: A Tale of Two Targets

    Managing Generalised Myasthenia Gravis: A Tale of Two Targets

    Visit https://www.peervoice.com/WVF860 to view the entire programme with slides. After completing “Managing Generalised Myasthenia Gravis: A Tale of Two Targets”, participants will be able to: Summarise the pathogenic contributors in generalised myasthenia gravis (gMG) and their role in disease progression; Translate the clinical data for emerging therapies for uncontrolled gMG in the context of current clinical practice; and Appraise how emerging therapies could evolve the standard of care for patients with uncontrolled gMG.

    • 1 hr
    Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias

    Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias

    Visit https://www.peervoice.com/XEK860 to view the entire programme with slides. After completing “Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias”, participants will be able to: Summarise the burden of anaemia and thrombocytopenia in patients with myelofibrosis (MF); Describe the benefits and limitations of current JAK inhibitors in the management of patients with myelofibrosis; and Propose how emerging therapies and regimens that may address anaemia/thrombocytopenia, constitutional symptoms, and splenomegaly may impact the future management of myelofibrosis in both JAK-inhibitor-naïve and JAK-inhibitor-experienced patients.

    • 18 min
    IAP Antagonists in Oncology: What Do We Know?

    IAP Antagonists in Oncology: What Do We Know?

    Visit https://www.peervoice.com/HDF860 to view the entire programme with slides. After completing “IAP Antagonists in Oncology: What Do We Know?”, participants will be able to: Describe the rationale for targeting IAP (inhibitor of apoptosis) in oncology; Identify the IAP antagonists most advanced in clinical development as anti-cancer treatments; and Evaluate how the clinical data for IAP antagonists are informing the potential for these agents in future clinical algorithms.

    • 23 min
    Advanced Therapy for CPF in Crohn's: Evaluating the Evidence for Stem Cell Therapy and More

    Advanced Therapy for CPF in Crohn's: Evaluating the Evidence for Stem Cell Therapy and More

    Visit https://www.peervoice.com/CCV860 to view the entire programme with slides. After completing “Advanced Therapy for CPF in Crohn's: Evaluating the Evidence for Stem Cell Therapy and More”, participants will be able to: Summarise key findings from the literature on advanced treatment options for complex perianal fistula (CPF) in Crohn’s disease; Review the strengths and limitations of these data in the context of current practice for CPF; and Describe the impact of these data on clinical practice.

    • 19 min
    Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC

    Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC

    Visit https://www.peervoice.com/DVG860 to view the entire programme with slides. After completing “Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC”, participants will be able to: Explain the importance of and current guidelines for MET exon 14-skipping (METex14) mutation testing in patients with NSCLC; Evaluate the efficacy and safety of current treatment options for patients with MET exon 14-skipping NSCLC; and Apply practical strategies to management of patients with MET exon 14-skipping NSCLC, including prevention and management of treatment-related adverse events.

    • 37 min
    Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022

    Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022

    Visit https://www.peervoice.com/YWF860 to view the entire programme with slides. After completing “Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022”, participants will be able to: Describe key safety and efficacy data for targeted and immunotherapies in molecular biomarker-positive non-small-cell lung cancer (NSCLC); Determine the impact and clinical implications of new evidence on the current treatment landscape in NSCLC; and Apply new data to improve the care and outcomes of patients with NSCLC.

    • 19 min

Customer Reviews

4.5 out of 5
2 Ratings

2 Ratings

Top Podcasts In Science

Hidden Brain
Alie Ward
Sam Harris
Bloomberg
Neil deGrasse Tyson
NPR

You Might Also Like

More by PeerVoice

PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice